Soluble and Exosome-Bound α-Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity

Simple Summary Many cancers down-regulate the expression of major histocompatibility complex class I (MHC-I) to avoid recognition and elimination by the adaptive immune system. Natural Killer (NK) cells, as part of innate immunity, complement tumor recognition by their ability to sense foreign and malignant cells by the lack of major MHC-I expression. During development, NK cells learn to perceive physiological levels of self MHC-I as healthy in a process termed NK cell education. In the current study, we assessed whether the stimulation of natural killer T (NKT) cells could impact the tumor-killing ability of NK cells. We can show that stimulation with a well-established activator of NKT cells induces the preferential expansion of educated NK cells, and improves NK-cell-mediated tumor-killing of both MHC-I+ and MHC-I− tumor cells. Furthermore, this increased tumor-killing capacity of NK cells can be achieved by nanovesicle-mediated delivery, which is known to improve adaptive immunity as well. Our approach thus holds great potential for future cancer immunotherapy. Abstract Natural killer (NK) cells can kill target cells via the recognition of stress molecules and down-regulation of major histocompatibility complex class I (MHC-I). Some NK cells are educated to recognize and kill cells that have lost their MHC-I expression, e.g., tumor or virus-infected cells. A desired property of cancer immunotherapy is, therefore, to activate educated NK cells during anti-tumor responses in vivo. We here analyze NK cell responses to α-galactosylceramide (αGC), a potent activator of invariant NKT (iNKT) cells, or to exosomes loaded with αGC. In mouse strains which express different MHC-I alleles using an extended NK cell flow cytometry panel, we show that αGC induces a biased NK cell proliferation of educated NK cells. Importantly, iNKT cell-induced activation of NK cells selectively increased in vivo missing self-responses, leading to more effective rejection of tumor cells. Exosomes from antigen-presenting cells are attractive anti-cancer therapy tools as they may induce both innate and adaptive immune responses, thereby addressing the hurdle of tumor heterogeneity. Adding αGC to antigen-loaded dendritic-cell-derived exosomes also led to an increase in missing self-responses in addition to boosted T and B cell responses. This study manifests αGC as an attractive adjuvant in cancer immunotherapy, as it increases the functional capacity of educated NK cells and enhances the innate, missing self-based antitumor response.

[1]  Bijal A. Parikh,et al.  Control of Viral Infection by Natural Killer Cell Inhibitory Receptors , 2020, Cell reports.

[2]  R. Garje,et al.  The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma , 2020, Cancers.

[3]  M. Hammarskjold,et al.  Ly49R activation receptor drives self-MHC–educated NK cell immunity against cytomegalovirus infection , 2019, Proceedings of the National Academy of Sciences.

[4]  Jiyan Liu,et al.  Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment , 2019, Front. Pharmacol..

[5]  S. Gabrielsson,et al.  Allogenicity Boosts Extracellular Vesicle–Induced Antigen-Specific Immunity and Mediates Tumor Protection and Long-Term Memory In Vivo , 2019, The Journal of Immunology.

[6]  T. Kambayashi,et al.  IL‐15 and CD155 expression regulate LAT expression in murine DNAM1+ NK cells, enhancing their effectors functions , 2019, European journal of immunology.

[7]  P. Trikha,et al.  Education‐dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells , 2019, The Journal of allergy and clinical immunology.

[8]  A. S. Krupnick,et al.  Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer , 2018, Proceedings of the National Academy of Sciences.

[9]  S. Cardell,et al.  Type II NKT Cells: An Elusive Population With Immunoregulatory Properties , 2018, Front. Immunol..

[10]  Axel Theorell,et al.  Determination of essential phenotypic elements of clusters in high-dimensional entities—DEPECHE , 2018, bioRxiv.

[11]  Y. Li,et al.  Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. , 2017, Cancer letters.

[12]  S. Gabrielsson,et al.  Exosomes from antigen-pulsed dendritic cells induce stronger antigen-specific immune responses than microvesicles in vivo , 2017, Scientific Reports.

[13]  T. Ideker,et al.  MHC-I Genotype Restricts the Oncogenic Mutational Landscape , 2017, Cell.

[14]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[15]  H. Yin,et al.  Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. , 2017, Journal of hepatology.

[16]  M. Colonna,et al.  Expression of CD226 is associated to but not required for NK cell education , 2017, Nature Communications.

[17]  E. Alici,et al.  Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells , 2016, Scientific Reports.

[18]  M. Dominguez-Villar,et al.  Sensitivity of dendritic cells to NK‐mediated lysis depends on the inflammatory environment and is modulated by CD54/CD226‐driven interactions , 2016, Journal of leukocyte biology.

[19]  H. Sekhon,et al.  Influenza Virus Targets Class I MHC-Educated NK Cells for Immunoevasion , 2016, PLoS pathogens.

[20]  Olivier Lantz,et al.  Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC , 2015, Oncoimmunology.

[21]  T. Lakshmikanth,et al.  Retuning of Mouse NK Cells after Interference with MHC Class I Sensing Adjusts Self-Tolerance but Preserves Anticancer Response , 2015, Cancer Immunology Research.

[22]  Spencer J. Williams,et al.  Antigen Specificity of Type I NKT Cells Is Governed by TCR β-Chain Diversity , 2015, The Journal of Immunology.

[23]  T. May,et al.  Activated NKT cells imprint NK‐cell differentiation, functionality and education , 2015, European journal of immunology.

[24]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[25]  A. Makrigiannis,et al.  Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells. , 2014, Cancer research.

[26]  S. Anderson,et al.  Functional NK Cell Repertoires Are Maintained through IL-2Rα and Fas Ligand , 2014, The Journal of Immunology.

[27]  A. Agha,et al.  KLRG1+ NK Cells Protect T-bet–Deficient Mice from Pulmonary Metastatic Colorectal Carcinoma , 2014, The Journal of Immunology.

[28]  Susanne Gabrielsson,et al.  Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. , 2013, Cancer research.

[29]  L. Carayannopoulos,et al.  Markers of Nonselective and Specific NK Cell Activation , 2013, The Journal of Immunology.

[30]  J. Trowsdale,et al.  NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. , 2013, Blood.

[31]  S. Gabrielsson,et al.  Dendritic Cell–Derived Exosomes Need To Activate Both T and B Cells To Induce Antitumor Immunity , 2013, The Journal of Immunology.

[32]  A. Cerwenka,et al.  Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors , 2012, The Journal of experimental medicine.

[33]  T. Fehniger,et al.  Cytokine activation induces human memory-like NK cells. , 2012, Blood.

[34]  K. Hsu,et al.  Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. , 2012, The Journal of clinical investigation.

[35]  T. Lakshmikanth,et al.  Skewing of the NK Cell Repertoire by MHC Class I via Quantitatively Controlled Enrichment and Contraction of Specific Ly49 Subsets , 2012, The Journal of Immunology.

[36]  A. Mantovani,et al.  Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. , 2012, Blood.

[37]  S. Cardell,et al.  Invariant NKT cells limit activation of autoreactive CD1d-positive B cells , 2010, The Journal of experimental medicine.

[38]  Thomas Quast,et al.  Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs , 2010, Nature Immunology.

[39]  L. Lanier,et al.  “Unlicensed” Natural Killer cells dominate the response to cytomegalovirus infection , 2010, Nature Immunology.

[40]  三宅 亨 Poly I:C-induced activation of NK cells by CD8α[+] dendritic cells via the IPS-1 and TRIF-dependent pathways , 2010 .

[41]  A. Thiel,et al.  Education of hyporesponsive NK cells by cytokines , 2009, European journal of immunology.

[42]  C. Roth,et al.  Maturation of mouse NK cells is a 4-stage developmental program. , 2009, Blood.

[43]  P. Brodin,et al.  NK cell education: not an on-off switch but a tunable rheostat. , 2009, Trends in immunology.

[44]  Laurence Zitvogel,et al.  Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα , 2009, PloS one.

[45]  S. Gabrielsson,et al.  Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. , 2009, Blood.

[46]  Sofia Johansson,et al.  The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. , 2009, Blood.

[47]  A. Engert,et al.  Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function , 2008, PloS one.

[48]  J. Dayer,et al.  The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors , 2007, Arthritis research & therapy.

[49]  A. Diefenbach,et al.  Dendritic cells prime natural killer cells by trans-presenting interleukin 15. , 2007, Immunity.

[50]  K. Fairfax,et al.  NK Cell Maturation and Peripheral Homeostasis Is Associated with KLRG1 Up-Regulation1 , 2007, The Journal of Immunology.

[51]  G. Leclercq,et al.  KLRG1 binds cadherins and preferentially associates with SHIP-1. , 2007, International immunology.

[52]  D. Middleton,et al.  Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.

[53]  Vrajesh V. Parekh,et al.  Glycolipid antigen induces long-term natural killer T cell anergy in mice. , 2005, The Journal of clinical investigation.

[54]  L. Lybarger,et al.  Licensing of natural killer cells by host major histocompatibility complex class I molecules , 2005, Nature.

[55]  S. Nutt,et al.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer , 2005, The Journal of experimental medicine.

[56]  R. Vance,et al.  A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. , 2005, Blood.

[57]  F. Lemonnier,et al.  Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules , 2005, The Journal of experimental medicine.

[58]  T. D. de Gruijl,et al.  Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. , 2005, Clinical immunology.

[59]  M. Smyth,et al.  Close encounters of different kinds: Dendritic cells and NK cells take centre stage , 2005, Nature Reviews Immunology.

[60]  T. Waldmann,et al.  Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. , 2005, Blood.

[61]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[62]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[63]  Dolca Thomas,et al.  Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Steinman,et al.  The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation , 2004, The Journal of experimental medicine.

[65]  L. Zitvogel,et al.  Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells 1 , 2004, The Journal of Immunology.

[66]  U. Koszinowski,et al.  Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. , 2003, Immunity.

[67]  E. Grant,et al.  CD1-dependent dendritic cell instruction , 2002, Nature Immunology.

[68]  C. Théry,et al.  Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes , 2002, Nature Immunology.

[69]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[70]  P. Möller,et al.  Activating Immunity in the Liver. II. IFN-β Attenuates NK Cell-Dependent Liver Injury Triggered by Liver NKT Cell Activation1 , 2002, The Journal of Immunology.

[71]  L. Lanier,et al.  Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors , 2002, Science.

[72]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[73]  F. Leithäuser,et al.  Activating Immunity in the Liver. I. Liver Dendritic Cells (but Not Hepatocytes) Are Potent Activators of IFN-γ Release by Liver NKT Cells1 , 2001, The Journal of Immunology.

[74]  L. Lanier,et al.  Ligands for natural killer cell receptors: redundancy or specificity , 2001, Immunological reviews.

[75]  S. Seki,et al.  Mechanisms of the Antimetastatic Effect in the Liver and of the Hepatocyte Injury Induced by α-Galactosylceramide in Mice , 2001, The Journal of Immunology.

[76]  I. Saiki,et al.  Differential Regulation of Th1 and Th2 Functions of NKT Cells by CD28 and CD40 Costimulatory Pathways1 , 2001, The Journal of Immunology.

[77]  M. Smyth,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.

[78]  T. Mcclanahan,et al.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. , 2000, Immunity.

[79]  T. Hanke,et al.  NK cell expression of the killer cell lectin‐like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules , 2000, European journal of immunology.

[80]  H. Fujiwara,et al.  Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cells. , 2000, International immunology.

[81]  Y. Koezuka,et al.  Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. , 1999, Journal of immunology.

[82]  A. Ohta,et al.  The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells , 1999, The Journal of experimental medicine.

[83]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[84]  H. Ljunggren,et al.  Host MHC class I gene control of NK‐cell specificity in the mouse , 1997, Immunological reviews.

[85]  M. Taniguchi,et al.  Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. , 1997, Science.

[86]  H. Ljunggren,et al.  Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[87]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[88]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.